Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range

C.J. Bailey, N. Iqbal, C. T'joen, J.F. List

Research output: Contribution to journalArticle

Abstract

Aims: Many patients with type 2 diabetes are suboptimally managed with currently available therapies. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, has shown efficacy in reducing diabetic hyperglycaemia. This study assessed efficacy of three lower doses in recently diagnosed patients. Methods: This phase 3, randomized, double-blind, placebo-controlled study assigned treatment-naïve patients to placebo or dapagliflozin monotherapy (1, 2.5 or 5 mg) daily for 24 weeks. Patients were antidiabetic drug-naïve with inadequate glycaemic control [haemoglobin A1c (HbA1c) =7.0 and =10.0%]. The primary efficacy endpoint was change in HbA1c from baseline. Secondary endpoints included changes in body weight and fasting plasma glucose (FPG), and proportions achieving HbA1c
Original languageEnglish
Pages (from-to)951-959
Number of pages9
JournalDiabetes, Obesity and Metabolism
Volume14
Issue number10
DOIs
Publication statusPublished - Oct 2012

Fingerprint

Randomized Controlled Trials
Hemoglobins
Pharmaceutical Preparations
Sodium-Glucose Transporter 2
Placebos
Symporters
Body Weight Changes
Hypoglycemic Agents
Hyperglycemia
Type 2 Diabetes Mellitus
Fasting
Glucose
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Therapeutics

Keywords

  • dapagliflozin
  • diabetes mellitus
  • glycaemic control
  • SGLT2
  • sodium-glucose co-transporter 2
  • type 2 diabetes

Cite this

@article{963ee1c8df684b1a8734ffe14b982248,
title = "Dapagliflozin monotherapy in drug-na{\"i}ve patients with diabetes: a randomized-controlled trial of low-dose range",
abstract = "Aims: Many patients with type 2 diabetes are suboptimally managed with currently available therapies. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, has shown efficacy in reducing diabetic hyperglycaemia. This study assessed efficacy of three lower doses in recently diagnosed patients. Methods: This phase 3, randomized, double-blind, placebo-controlled study assigned treatment-na{\"i}ve patients to placebo or dapagliflozin monotherapy (1, 2.5 or 5 mg) daily for 24 weeks. Patients were antidiabetic drug-na{\"i}ve with inadequate glycaemic control [haemoglobin A1c (HbA1c) =7.0 and =10.0{\%}]. The primary efficacy endpoint was change in HbA1c from baseline. Secondary endpoints included changes in body weight and fasting plasma glucose (FPG), and proportions achieving HbA1c",
keywords = "dapagliflozin, diabetes mellitus, glycaemic control, SGLT2, sodium-glucose co-transporter 2, type 2 diabetes",
author = "C.J. Bailey and N. Iqbal and C. T'joen and J.F. List",
year = "2012",
month = "10",
doi = "10.1111/j.1463-1326.2012.01659.x",
language = "English",
volume = "14",
pages = "951--959",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "10",

}

Dapagliflozin monotherapy in drug-naïve patients with diabetes : a randomized-controlled trial of low-dose range. / Bailey, C.J.; Iqbal, N.; T'joen, C.; List, J.F.

In: Diabetes, Obesity and Metabolism, Vol. 14, No. 10, 10.2012, p. 951-959.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dapagliflozin monotherapy in drug-naïve patients with diabetes

T2 - a randomized-controlled trial of low-dose range

AU - Bailey, C.J.

AU - Iqbal, N.

AU - T'joen, C.

AU - List, J.F.

PY - 2012/10

Y1 - 2012/10

N2 - Aims: Many patients with type 2 diabetes are suboptimally managed with currently available therapies. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, has shown efficacy in reducing diabetic hyperglycaemia. This study assessed efficacy of three lower doses in recently diagnosed patients. Methods: This phase 3, randomized, double-blind, placebo-controlled study assigned treatment-naïve patients to placebo or dapagliflozin monotherapy (1, 2.5 or 5 mg) daily for 24 weeks. Patients were antidiabetic drug-naïve with inadequate glycaemic control [haemoglobin A1c (HbA1c) =7.0 and =10.0%]. The primary efficacy endpoint was change in HbA1c from baseline. Secondary endpoints included changes in body weight and fasting plasma glucose (FPG), and proportions achieving HbA1c

AB - Aims: Many patients with type 2 diabetes are suboptimally managed with currently available therapies. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, has shown efficacy in reducing diabetic hyperglycaemia. This study assessed efficacy of three lower doses in recently diagnosed patients. Methods: This phase 3, randomized, double-blind, placebo-controlled study assigned treatment-naïve patients to placebo or dapagliflozin monotherapy (1, 2.5 or 5 mg) daily for 24 weeks. Patients were antidiabetic drug-naïve with inadequate glycaemic control [haemoglobin A1c (HbA1c) =7.0 and =10.0%]. The primary efficacy endpoint was change in HbA1c from baseline. Secondary endpoints included changes in body weight and fasting plasma glucose (FPG), and proportions achieving HbA1c

KW - dapagliflozin

KW - diabetes mellitus

KW - glycaemic control

KW - SGLT2

KW - sodium-glucose co-transporter 2

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84866003015&partnerID=8YFLogxK

UR - http://onlinelibrary.wiley.com/doi/10.1111/j.1463-1326.2012.01659.x/abstract

U2 - 10.1111/j.1463-1326.2012.01659.x

DO - 10.1111/j.1463-1326.2012.01659.x

M3 - Article

AN - SCOPUS:84866003015

VL - 14

SP - 951

EP - 959

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 10

ER -